LGVN - Public offerings

$15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled.ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in late 2026, if ELPIS II results are positiveStem cell therapy pipeline expanded with FDA approval of IND application for laromestrocel as a potential treatment for Pediatric Dilated CardiomyopathyCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, Au

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term w

MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an ex

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approvalPositive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B™ in Alzheimer's disease presented in Featured Research Oral Presentation at Alzheimer's Association International Conference® (AAIC)Total Revenue for the first nine months of 2024 increased 177% year-over-year to $1.8 million, primarily due to the successful initiation of contract manufacturing services and increas

Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer's disease presented in Featured Research Oral Presentation at Alzheimer's Association International Conference® (AAIC)U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer's diseasePhase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved 70% enrollment with completion of enrollment targeted for the end of 2024Strengthened Board of Directors with election of 3 experienced industry veterans at Annual MeetingFocused expenditure management reduced first half T

MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agr

MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024. The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants,

MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced public offering of up to 2,234,043 shares of the Company's Class A common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of Class A common stock at a combined offering price of $2.35 per share (or per pre-funded warrant in lieu thereof) and associated warrant. The wa

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the pricing of a public offering of 2,234,043 shares of the Company's Class A common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of Class A common stock at a combined offering price of $2.35 per share (or per pre-funded warrant in lieu thereof) and associated warrant. The warrants will have an exercise pric

MIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,355,301 shares of its Class A common stock ("common stock") at a purchase price of $1.745 per share and associated warrant. In a concurrent private placement, Longeveron issued unregistered warrants to purchase up to an

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.745 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase u

Top Line Results from CLEAR MIND Alzheimer's disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association $4 Million in Equity Financing Secured in Registered Direct Offering ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Company to Hold Conference Call and Webcast Today, November 10, 2023 at 8:30am Eastern Time MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clin

MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 2,424,243 shares of its Class A common stock ("common stock") or common stock equivalents in lieu thereof, at a purchase price of $1.65 per share, or per common stock equivalent in lieu thereof. In addition, in a concurren

MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock ("common stock"), or common stock equivalents in lieu thereof, at a purchase price of $1.65 per share, or per common stock equivalent in lieu thereof, in a registered direct offering priced at-the-market under Nasdaq ru

MIAMI, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announces that Wa'el Hashad, Chief Executive Officer of Longeveron, has issued a Letter to Stockholders providing a business update. Full text of the letter, which has been posted to the Company's website, is as follows: Dear Fellow Stockholders: When I joined Longeveron as CEO, I was intrigued by the potential of our lead investigational product Lomecel-B™

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announced it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. Longeveron's research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company's ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA). The poster, titled Long-term Transplant-free Survival Is Improved in Hypoplasti

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 , 2023 in New York, NY. Wa'el Hashad, Chief Executive Officer of Longeveron, will give a pre-recorded presentation highlighting the Company's cellular therapy programs, which will be available on-dema

MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that the Company's management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023. Wa'el Hashad, Chief Executive Officer of Longeveron, will give a presentation highlighting the Company's cellular therapy programs, and the Company's execut

MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that the subscription period for its previously announced rights offering has begun. The subscription price is $3.00 per share. The subscription period for the rights offering ends at 5:00 p.m. Eastern Time on Thursday, September 21, 2023, unless extended at the Company's sole discretion. Longeveron reserves the right to modify, extend, postpon

MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar. The rights offering is being made through a distribution of five tradable subscription rights (to be listed on The NASDAQ Capital

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET. Click here to register and attend. The event will feature Sunjay Kaushal, MD, PhD (Northwestern University Feinberg School of Medicine) and Ram Kumar Subramanyan, MD, PhD (Chief of Pediatric Cardiothoracic Surgery at Children's Hospital and Medical Center, Omaha and Professor of Surgery at University of Nebraska Medical Center) who will discuss the unmet medical need and current standard of care for patients

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock. The rights offering is being made through a distribution of five tradable subscription rights (to be

MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as Alzheimer's Disease and Aging Frailty, announced today that it has filed a registration statement with the Securities and Exchange Commission ("SEC") to conduct a tradeable subscription rights offering to its shareholders and holders of warrants to purchase common stock as of a future record date to be determined. Longeveron's registration statement on Form S-1 covers a rights offering for up to $30,000,000 of shares of common stock. Under the terms of the r

-- Full results from ELPIS I trial published in European Heart Journal Open –         -- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, March 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022. "Longeveron had a productive 2022, executing on multiple key mile

—Longeveron's Phase 2a trial of Lomecel-B for patients with mild Alzheimer's Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin – Top-line findings from the second phase of the Phase 1/2 HERA trial show that the primary endpoint for safety was met in the randomized placebo-controlled portion of the study –$27 million in cash, cash equivalents and short-term investments as of June 30, 2022, expected to be sufficient to fund operations into 2024 –Conference call scheduled for 8:30 a.m. ET today–

Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer's Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLHS Granted Rare Pediatric Disease and Orphan Drug Designation by the US FDA Japanese Phase 2 Aging Frailty Trial Expected to Initiate in First Half of 2022 Multiple Clinical Data Publications Expected in 2022 - Conference Call Today at 8:30 a.m. EST - MIAMI, March 11, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) (the "Company," "Longeveron" or "we," "us," or "our"), a clinical stage biopharmaceutical company developing cellular the

MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants. The Company sold approximately 1.17 million shares of its common stock and 1.17 million warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of c

MIAMI, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding the status of the Company's various clinical research programs and reported its financial results for the quarter ended September 30, 2021. "In the third quarter of 2021, we continued executing across our pipeline," said Geoff Green, CEO of Longeveron. "With a growing base of encouraging clinical data, we continue to make excellent progress in advancing our lead candidate, Lomecel-B, into next phase trials. In addition to

MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the quarter ended June 30, 2021. "We continue to make excellent progress advancing our Lomecel-B clinical research programs forward," said Geoff Green, CEO of Longeveron. "Today we announced encouraging top-line results from our Phase 2b Aging Frailty trial evaluating the safety and efficacy of four different doses of Lomecel-B compared to placebo in Aging Frailty subjects. And, we anticipate a

Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B compared to placebo Complete results being prepared for publication. On track to initiate Phase 2 study in the second half of 2021. MIAMI, April 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) announced today the final results of its Phase I clinical study evaluating the safety and efficacy of intravenous (i.v.) administration of Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) p

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full year ended December 31, 2020 and provided a business update. Primary Accomplishments in 2020: Received approval from U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical trial for Acute Respiratory Distress Syndrome (ARDS) related to either COVID-19 or Influenza infection. This trial initiated in mid-2020 and continues to enroll subjects.Received a $650,000, two-year Maryland

MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previously completed initial public offering of Class A common stock have partially exercised their over-allotment option to purchase an additional 250,000 shares. The thirty-day over-allotment option was granted in connection with the Company’s initial public offering of 2,660,000 shares of Class A common stock at a public offering price of $10.00. After giving effect to the partial exercise of the over-allotment op